Anivive Lifesciences Receives $20M Funding from Leonid Capital Partners to Develop Novel Programs for Pets
Shots:
- Anivive secured a $20M investment from Leonid to advance research of its programs, expand manufacturing, & support the marketing of its valley fever vaccine for canines
- Funding follows a $33M NIAID contract with NIH to develop human vaccine for the fungus Coccidioides, which causes Valley fever, leading to ~$80M in preorders & contracts
- Anivive leverages its AI platform to accelerate drug discovery & development by repurposing human treatments for veterinary oncology, antivirals, & antifungal vaccines. Additionally, its direct-to-veterinarian sales platform, Engage, has processed ~9,000 orders since its launch in early 2024
Ref: PRNewswire | Image: Pet Honesty
Related News:- Virbac Launches Zenifel Pheromone Product to Address Stress-Related Behaviors in Cats
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
